Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop FX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
IPO Year: 2014
Exchange: NASDAQ
Website: xenon-pharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | $50.00 | Outperform | Raymond James |
| 10/1/2024 | $53.00 | Buy | H.C. Wainwright |
| 1/4/2024 | $62.00 | Buy | Citigroup |
| 12/8/2023 | $63.00 | Outperform | Robert W. Baird |
| 10/24/2023 | Overweight | Cantor Fitzgerald | |
| 4/25/2023 | $58.00 | Overweight | Cantor Fitzgerald |
| 12/14/2022 | $60.00 | Buy | Goldman |
| 12/12/2022 | Outperform | Cowen | |
| 11/28/2022 | $50.00 | Overweight | Wells Fargo |
| 10/19/2022 | $52.00 | Outperform | Raymond James |
VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its third quarter 2024 financial results after the close of U.S. financial markets on Tuesday, November 12, 2024. Conference Call/Webcast Information: Date: Tuesday, November 12, 2024 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID:7128308 A live webcast of the com
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference taking place October 7, 2024. Fireside Chat Presentation Details: Date:Monday, October 7, 2024 Time:11:40 am Eastern Time Webcast:Register here A live webcast of the company presentation will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates an
Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced three poster presentations at the 15th European Epilepsy Congress (EEC) taking place in Rome, Italy. Azetukalner, a novel, potent Kv7 channel opener, is the most advanced, clinically validated potassium channel modulator in late-stage development for multiple indications, including focal on
VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr. Ronsheim will lead Chemistry, Manufacturing and Controls (CMC), Program Management and Quality Assurance and as a member of the senior executive team will be responsible for providing strategic and operational leadership for the Company's pipeline of small molecule progr
— Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025— MDD program on track with Phase 3 study expected to initiate in H2 2024— Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in 2025— Conference call at 4:30 pm ET today VANCOUVER, British Columbia, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. "We are proud to have the only Kv7
VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. Conference Call/Webcast Information: Date:Thursday, August 8, 2024Time:4:30 pm Eastern Time (1:30 pm Pacific Time)Webcast:Pre-register hereDial-In:(800) 715-9871 toll-free, or (646) 307-1963 for international callersConference ID:1631616 The live audio webcast can be accessed on t
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in Miami, FL. Fireside Chat Presentation Details: Date:Wednesday, June 12, 2024Time:4:00 pm Eastern TimeWebcast:Register herePresenters:Ian Mortimer, President and Chief Executive OfficerChris Von Seggern, Chief Commercial Officer A live webcast of the company presentation will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL. Mr. Ian Mortimer, Xenon's President and Chief Executive Officer, stated, "We are pleased to present these data from our Phase 2 proof-of-concept X-NOVA study of azetukalner in MDD at the ASCP meeting. The X-NOVA results demonstrated a clinically meaningful reduction in depression, in addition to an early onset of action, a signifi
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful "end-of-Phase 2" interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azetukalner now the international nonproprietary name (INN) and United States adopted name (USAN) for XEN1101 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update. Mr. Ian Mortimer, Xeno
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV. Fireside Chat Presentation Details:Date:Wednesday, May 15, 2024Time:3:40 pm Pacific Time (6:40 pm Eastern Time)Webcast:Register herePresenters:Ian Mortimer, President and Chief Executive OfficerSherry Aulin, Chief Financial Officer A live webcast of the company presentation will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr. Ronsheim will lead Chemistry, Manufacturing and Controls (CMC), Program Management and Quality Assurance and as a member of the senior executive team will be responsible for providing strategic and operational leadership for the Company's pipeline of small molecule progr
BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. Ms. DiFabio will provide strategic leadership and oversight of the planning and execution for Xenon's legal function on a global basis. Mr. Ian Mortimer, Xenon's President and Chief Executive Officer, stated, "We are very pleased to welcome Andrea to Xenon's senior leadership team in the newly created role of Chief Legal Officer. Andrea joins us at a time when we have multiple late-stage clinical programs underway with the
BURNABY, British Columbia, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Christopher Kenney, M.D. as Chief Medical Officer, effective immediately. Dr. Kenney will oversee all clinical development and medical affairs strategies, guiding the development of Xenon's portfolio of neurology-focused therapeutic programs. Mr. Ian Mortimer, Xenon's President and Chief Executive Officer, stated, "We are thrilled to welcome Chris to the Xenon senior leadership team as we enter an important period with multiple mid- to late-stage programs advancing within our neurology pipeline and continue
Simon Pimstone to Assume New Role as Executive Chair and Ian Mortimer to be Named Chief Executive Officer at Annual Meeting of Shareholders in June 2021 Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021 Phase 3 XEN496 “EPIK” Clinical Trial Initiated in Patients with KCNQ2-DEE, a Rare Orphan Pediatric Disease BURNABY, British Columbia, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestone opportunities and plans for a leadership transition in 2021, with all changes anticipated to take effect in June 2021 at the time of th
RBC Capital analyst Brian Abrahams reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and maintains $55 price target.
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and maintains $62 price target.
Citigroup analyst David Hoang maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $62 to $60.
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $51 to $50.
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.66) by 6.06 percent.
Xenon's Oral Presentations at AANOral Presentation #005 (French et al.) "Interim, Long-term, Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in Adults with Focal Epilepsy."Session 19: Epilepsy Clinical Trials and Long-term StudiesOral Presentation #004 (Porter et al.) "The Impact of Disease Severity on Responder Rates in a Phase 2b Study of XEN1101, a Potent, Selective Potassium Channel Opener, in Adults With Focal Epilepsy (X-TOLE)."Session 19: Epilepsy Clinical Trials and Long-term StudiesXenon is also hosting Booth #1797 in the AAN Exhibit Hall, which runs until Wednesday, April 17, 2024
Needham analyst Serge Belanger reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and maintains $62 price target.
Cantor Fitzgerald analyst Josh Schimmer reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and maintains $65 price target.
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $56 to $55.
Raymond James resumed coverage of Xenon Pharmaceuticals with a rating of Outperform and set a new price target of $50.00
H.C. Wainwright initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $53.00
Citigroup initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $62.00
Robert W. Baird initiated coverage of Xenon Pharmaceuticals with a rating of Outperform and set a new price target of $63.00
Cantor Fitzgerald resumed coverage of Xenon Pharmaceuticals with a rating of Overweight
Cantor Fitzgerald initiated coverage of Xenon Pharmaceuticals with a rating of Overweight and set a new price target of $58.00
Goldman initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $60.00
Cowen initiated coverage of Xenon Pharmaceuticals with a rating of Outperform
Wells Fargo initiated coverage of Xenon Pharmaceuticals with a rating of Overweight and set a new price target of $50.00
Raymond James initiated coverage of Xenon Pharmaceuticals with a rating of Outperform and set a new price target of $52.00
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its third quarter 2024 financial results after the close of U.S. financial markets on Tuesday, November 12, 2024. Conference Call/Webcast Information: Date: Tuesday, November 12, 2024 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID:7128308 A live webcast of the com
— Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025— MDD program on track with Phase 3 study expected to initiate in H2 2024— Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in 2025— Conference call at 4:30 pm ET today VANCOUVER, British Columbia, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. "We are proud to have the only Kv7
VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. Conference Call/Webcast Information: Date:Thursday, August 8, 2024Time:4:30 pm Eastern Time (1:30 pm Pacific Time)Webcast:Pre-register hereDial-In:(800) 715-9871 toll-free, or (646) 307-1963 for international callersConference ID:1631616 The live audio webcast can be accessed on t
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful "end-of-Phase 2" interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azetukalner now the international nonproprietary name (INN) and United States adopted name (USAN) for XEN1101 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update. Mr. Ian Mortimer, Xeno
VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, May 9, 2024. Conference Call/Webcast Information: Date:Thursday, May 9, 2024 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast:Pre-register here Dial-In: (800) 715-9871 toll-free, or (646) 307-1963 for international callers The live audio webcast can be accessed on the Investors section of the Xenon website. Participants are encouraged to pre-register for the conference call in order to
XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in X-TOLE2 expected in late 2024 to early 2025 Planned "end-of-Phase 2" meeting with the FDA in April to support the initiation of XEN1101 Phase 3 program in major depressive disorder in the second half of the year Strong financial position with approximately $930 million to fully support XEN1101 Phase 3 programs in epilepsy and major depressive disorder and expected cash runway into 2027 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, Feb. 29, 202
VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year 2023 financial and operating results after the close of U.S. financial markets on Thursday, February 29, 2024. Conference Call/Webcast Information: Date: Thursday, February 29, 2024Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)Dial-In: (800) 715-9871 or (646) 307-1963 for international callersConference ID: 9376408 A live audio webcast will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe major depressive disorder, or MDD. Summary of Efficacy Data The primary endpoint of the study was a change in the Montgomery-Åsberg Depression Rating Scale, or MADRS, at week 6. The mean reduction was 13.90 in the placebo group, 15.61 in the XEN1101 10 mg group and 16.94 in t
Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder on track for late November to mid-December XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures Patient enrollment in X-TOLE2 expected to complete in the second half of 2024 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update. Mr. Ian Mortimer
VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, November 8, 2023. Conference Call/Webcast Information: Date:Wednesday, November 8, 2023 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Dial-In:(800) 715-9871 or (646) 307-1963 for international callers Conference ID:4249948 A live audio webcast will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are sub
S-3ASR - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
10-Q - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
S-8 - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
10-Q - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
ARS - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
DEF 14A - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)